Science 37 Gets $29M To Extend Clinical Trials To Patient Homes

Playa Vista-based Science 37, which is developing technology and a model that allows pharmaceuticals companies and others to conduct clinical trials in patients' homes--rather than dedicated, off-site facilities--has raised $29M in a Series C funding round. The round was led by Glynn Capital Management, and also included GV (formerly Google Ventures), plus Amgen Ventures, Lux Capital, Redmile Group, dRx Capital (a Qualcomm and Novartis joint investment company), and Sanofi Ventures. The company says it ihas now raised almost $67M in total. Science 37 uses telemedicine, traveling nurses, and other technology which helps companies conducting clinical trials to reach hard to reach patient groups, including minorities, cancer patients, and others who are far away from research-focused medicial facilities. Science 37 is led by CEO Noah Craft. More information »